|
Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] >>
|
 |
...with Parkinson’s disease to participate in Neuroprotection Exploratory Trials in.....Neuroprotection Exploratory Trials in.....to find drugs to slow the progression of Parkinson’s. ...
|
| |
|
|
 |
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: PARKINSON DISEASE NEUROPROTECTION CLINICAL TRIAL: CLINICAL CENTERS...
|
| |
|
|
 |
...Perspective"; "Neuroprotection and Parkinson's Disease"; "Neuroprotection and.....the MS Center of Excellence-West and the Parkinson's Disease Research, Education.....S EVENT.. WHAT: ...
|
| |
|
|
 |
PARKINSON DISEASE NEUROPROTECTION CLINICAL TRIAL: CLINICAL CENTERS RELEASE DATE: September 2, 2004 RFA Number: RFA-NS-05-004 EXPIRATION DATE: January 25, 2005 Department of Health and Human ...
|
| |
|
|
 |
Neurodegeneration and Neuroprotection in Parkinson Disease Stanley Fahn ... and ... David Sulzer...
|
| |
|
|
 |
Green tea extract and its main polyphenol constituent (-)-epigallocatechin-3-gallate (EGCG) possess potent neuroprotective activity in cell culture and mice model of Parkinson's disease. ...
|
| |
|
|
 |
... this article is cited Topic Collections Neurology Review Topic Collection Alerts Neuroprotection in Parkinson Disease Nicole Simpkins, BA ; Joseph Jankovic, MD Arch Intern ...
|
| |
|
|
 |
An Original Articleby Manuchair Ebadi, Jorge F. Rodriguez-Sierra and Neil S. Norton in the Neuroendocrinology Letters Vol.18 No.2/2, 1997, p.111-122 ... stress and to provide ...
|
| |
|
Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] >>
|
